 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 1397 | 回復: 4 | |||
| 當前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | |||
[交流]
FDA會認可中國做的數(shù)據(jù)嗎 已有4人參與
|
|||
|
在國內做抗腫瘤活性測試(如 國家新藥篩選中心)后, 將來美國FDA會認可這些數(shù)據(jù)嗎? 其它比如毒性試驗, 臨床試驗等在國內做, 將來美國FDA會認可這些數(shù)據(jù)嗎? |
回復此樓» 猜你喜歡
華南理工大學-醫(yī)學院-藥學專碩少量調劑名額
已經有28人回復
-
求助《生物利用度和生物等效性研究指導原則》（試 行），2002
已經有0人回復
-
藥物學論文潤色/翻譯怎么收費?
已經有115人回復
-
文獻求助
已經有0人回復
» 本主題相關價值貼推薦，對您同樣有幫助:
- FDA中的AERs數(shù)據(jù)庫
已經有5人回復
- 請問EIS阻抗數(shù)據(jù)用辰華的660測試，國際期刊認可這個儀器的結果嗎？
已經有4人回復
3樓2012-09-25 13:05:06
muziqian38
鐵蟲 (初入文壇)
- 應助: 0 (幼兒園)
- 金幣: 61.7
- 帖子: 14
- 在線: 2小時
- 蟲號: 1237577
- 注冊: 2011-03-18
- 性別: MM
- 專業(yè): 藥物化學
★ ★ ★ ★
小木蟲: 金幣+0.5, 給個紅包，謝謝回帖
癡夷子皮: 金幣+3, 熱心獎勵 2012-09-25 08:16:47
小木蟲: 金幣+0.5, 給個紅包，謝謝回帖
癡夷子皮: 金幣+3, 熱心獎勵 2012-09-25 08:16:47
|
我?guī)湍惆俣攘艘幌�。有一個帖子和你類似。原文是 各位大俠，最近偶讀到一篇文章，說美國FDA認可了一個治療肝炎的藥物在中國做的臨床試驗數(shù)據(jù)。本人未能查到出處，不知哪位知情可否告知。 其中有一個回帖。如下。希望對你有幫助。 美國FDA承認的研究： Entecavir Is Superior to Epivir-HBV in Reducing HBV DNA Levels Among Patients with Chronic Hepatitis B By Ronald Baker, PhD There are currently 3 FDA-approved agents for the treatment of chronic hepatitis B: Epivir-HBV (GlaxoSmithKline), Intron A (Schering-Plough) and Hepsera (Gilead Sciences). A number of new agents are in development for the treatment of hepatitis B. Entecavir is a promising new experimental nucleoside analog drug from Bristol-Myers Squibb that has entered Phase III clinical trials for efficacy, the final stage of testing prior to FDA evaluation for approval as a prescription drug. Entecavir shows superior effectiveness compared to Epivir-HBV (lamivudine; 3TC) in reducing HBV DNA levels in patients with chronic HBV, according to results of a Phase II study published in the December issue of Gastroenterology. The 24-week randomized, double blind study was conducted in 169 patients with chronic hepatitis B. The multicenter study took place at sites in China, Malaysia, The Philippines, Belgium, Canada and the US. The safety and efficacy of entecavir at various doses (0.01 mg/day, 0.1 mg/day, or 0.5 mg/day orally) were compared with Epivir-HBV (100 mg/day orally). Patients with chronic HBV (hepatitis B "e" antigen [HBeAg]-positive and -negative) were evaluated for efficacy using the two treatments. Compared with Epivir-HBV, entecavir reduced HBV DNA by an additional 0.97 log (10) at the 0.1-mg/day dose and an additional 1.28 log (10) at the 0.5-mg/day dose (P < 0.0001). A clear dose-response relationship was observed for entecavir with the higher doses showing significantly greater HBV suppression. In patients treated with entecavir 0.5 mg/day, 83.7% had an HBV-DNA level below the lower limit of detection of the Quantiplex branched DNA (bDNA) assay (Bayer-Versant Diagnostics), compared with 57.5% treated with 100 mg/day lamivudine (P = 0.008). In both treatment arms, very few patients achieved HBeAg loss and/or seroconversion by week 22. More patients treated with the 0.1-mg/day and 0.5-mg/day doses of entecavir had normalization of alanine transaminase (ALT) levels at week 22 compared with lamivudine (P = not significant). Entecavir was well tolerated; most adverse events were mild to moderate, transient, and comparable in all study arms. The authors conclude, "This study showed that entecavir has potent antiviral activity against HBV at 0.1-mg/day and 0.5-mg/day doses, both of which were superior to lamivudine in chronically infected HBV patients." 1/03/03 Reference CL Lai and others. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002 Dec; 123: 1831-1838. Entecavir at Two Low Doses Demonstrates Potent Anti-HBV Activity in Phase II Trial in China Entecavir (ETV) is a novel hepatitis B antiviral agent with potent selective activity against the hepatitis B virus (HBV). This is the first phase II trial conducted in China with entecavir. The purpose of this study is to determine the proportion of subjects in the ETV and placebo treatment groups who demonstrate an antiviral response at the end of the 28-day dosing period as measured by either a ?2 log10 reduction in HBV DNA by bDNA assay or undetectable HBV DNA by bDNA assay plus a ? 2 log10 reduction in HBV DNA by PCR assay. This is an ongoing study in Chinese adults with chronic hepatitis B infection (HBeAg-positive and -negative) with less than 12 weeks of prior anti-HBV nucleoside therapy. The study has four phases: (1) a randomized 28-day double-blind dosing phase of two doses of ETV (0.1 and 0.5 mg once daily) compared with placebo; (2) a 56-day post-dosing phase; (3) a 48-week open-label ETV 0.5 mg once daily dosing phase; and (4) a 24-week post open-label follow-up phase. Results from the 28-day double blind dosing phase and 56-day post-dosing phase are presented here. Study Results 216 patients were randomized (1:1:1) in the study and 212 patients received at least one dose of study medication. The majority of the subjects were male (74%), all were Asian, 96% were HBeAg-positive and the mean age was 30 years. The three treatment groups (ETV 0.1 mg, ETV 0.5 mg, placebo) were similar in terms of median baseline HBV DNA level by bDNA assay (3.18, 3.04, 3.08 MEq/mL, respectively) and median baseline ALT values (57.0, 59.5, 64.0 U/L). Entecavir 0.1 and 0.5 mg doses were superior to placebo for the primary endpoint of reducing HBV DNA levels at Day 28 (86%, 93%, 3%, respectively; p < 0.0001). The mean change from baseline in HBV DNA levels at Day 28 for the ETV 0.1 mg, 0.5 mg, and placebo groups as determined by bDNA assay were -2.51, -2.73, and -0.12 log10 MEq/mL, respectively. In the 56-day post-dosing phase, the ETV 0.5 mg dose was associated with greater viral suppression than the 0.1 mg dose. The most common clinical adverse events (> 5% incidence) were fatigue, somnolence, dizziness, insomnia and rhinitis. There were no meaningful differences between the entecavir and placebo groups in the incidence of adverse events on treatment. Conclusion Entecavir at both 0.1 and 0.5 mg doses demonstrated potent antiviral activity compared with placebo, as measured by reduction in HBV DNA viral load over a 28-day treatment period. Both the 0.1 and 0.5 mg doses of ETV administered once daily for 28 days were safe and well tolerated. 11/05/03 Reference G Yao and others. A PHASE II STUDY IN CHINA OF THE SAFETY & ANTIVIRAL ACTIVITY OF ENTECAVIR IN ADULTS WITH CHRONIC HEPATITIS B INFECTION. Abstract 1143 (poster). 54th Annual Meeting of the American Association for the Study of Liver Diseases. October 24-28, 2003. Boston, MA. http://www.hivandhepatitis.com/hep_b/news/entecavir.html |
2樓2012-09-24 17:32:15
★ ★
小木蟲: 金幣+0.5, 給個紅包，謝謝回帖
zhychen2008: 金幣+1, 感謝回帖交流 2012-10-07 16:41:29
小木蟲: 金幣+0.5, 給個紅包，謝謝回帖
zhychen2008: 金幣+1, 感謝回帖交流 2012-10-07 16:41:29
|
說說美國人的思維，美國人既是辦事認真又是態(tài)度靈活的一群人。至于美國人認不認中國的數(shù)據(jù)，要看中國自己的情況了。 舉個例子，美國FDA的官員來中國審核某企業(yè)的車間，要求出具相應的SOP，并且審查得非常細致，還要當面核對，從這點上來說是很嚴格的。但科研又是另一種情況了，在硬件、軟件達標的前提下，一些研究是沒有硬性規(guī)定的，只要你的研究能充分說明問題就OK。 中國人辦事的一個典型思路就是領導要求的就是我必須辦理的，美國不是啊，F(xiàn)DA只是負責審核、配合申辦者的工作，申辦者具有很高的主動權。要想獲得美國的認可，首先應贏得自己的認可和專家的認可。 |
4樓2012-09-25 13:16:24
yaowushuo
捐助貴賓 (小有名氣)
- 應助: 2 (幼兒園)
- 金幣: 474.9
- 帖子: 124
- 在線: 17.6小時
- 蟲號: 233678
- 注冊: 2006-03-30
- 性別: GG
- 專業(yè): 藥物化學
5樓2012-10-06 17:33:17
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 265求調劑 +8 | 梁梁校校 2026-03-17 | 8/400 |
|
|---|---|---|---|---|
|
|
[考研] 290求調劑 +4 | ^O^乜 2026-03-19 | 4/200 |
|
|
[考研] 材料與化工求調劑 +7 | 為學666 2026-03-16 | 7/350 |
|
|
|
[考研] 一志愿 西北大學 ，070300化學學碩，總分287，雙非一本，求調劑。 +3 | 晨昏線與星海 2026-03-19 | 3/150 |
|
|
|
[考研] 一志愿中海洋材料工程專碩330分求調劑 +7 | 小材化本科 2026-03-18 | 7/350 |
|
|
|
[考研] 一志愿985，本科211，0817化學工程與技術319求調劑 +10 | Liwangman 2026-03-15 | 10/500 |
|
|
|
[考研] 344求調劑 +6 | knight344 2026-03-16 | 7/350 |
|
|
|
[考研] 一志愿武理材料305分求調劑 +5 | 想上岸的鯉魚 2026-03-18 | 6/300 |
|
|
|
[考研] 311求調劑 +6 | 26研0 2026-03-15 | 6/300 |
|
|
|
[考研] 312求調劑 +8 | 陌宸希 2026-03-16 | 9/450 |
|
|
|
[考研] 280求調劑 +6 | 咕嚕曉曉 2026-03-18 | 7/350 |
|
|
|
[考研] 生物學071000 329分求調劑 +3 | 我愛生物生物愛?/a> 2026-03-17 | 3/150 |
|
|
|
[考博] 26博士申請 +3 | 1042136743 2026-03-17 | 3/150 |
|
|
|
[考研] 一志愿蘇州大學材料工程（085601）專碩有科研經歷三項國獎兩個實用型專利一項省級立項 +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
|
[論文投稿] 有沒有大佬發(fā)小論文能帶我個二作 +3 | 增銳漏人 2026-03-17 | 4/200 |
|
|
|
[考研] 藥學383 求調劑 +3 | 藥學chy 2026-03-15 | 4/200 |
|
|
|
[基金申請]
今年的國基金是打分制嗎？
 50+3
|
zhanghaozhu 2026-03-14 | 3/150 |
|
|
|
[考研] 一志愿哈工大材料324分求調劑 +5 | 閆旭東 2026-03-14 | 5/250 |
|
|
|
[考研] 招收0805（材料）調劑 +3 | 18595523086 2026-03-13 | 3/150 |
|
|
|
[考研] 311求調劑 +3 | 冬十三 2026-03-13 | 3/150 |
|